TORONTO — Health Canada has licensed two new blood-based neurological testing products, potentially expanding access to emerging biomarkers used in the assessment of neurological conditions.

Fujirebio announced Tuesday that Health Canada has granted Class II medical device licences for its Lumipulse G NfL Blood Assay and Lumipulse G pTau 217 Plasma Assay.

The tests measure two important biomarkers. Neurofilament light chain (NfL) is associated with nerve-cell injury, while phosphorylated tau 217 (pTau 217) is an increasingly important biomarker in Alzheimer’s disease research and clinical assessment.

The availability of blood-based biomarkers could make neurological testing more convenient than approaches that require more invasive procedures, although the clinical role and interpretation of such tests depend on healthcare professionals and the specific patient situation.

The development comes as researchers and diagnostic companies increasingly focus on blood-based testing for brain health, seeking easier ways to identify biological signals associated with neurological disease.

The new Canadian licences mark another step toward expanding the country’s access to advanced neurological diagnostics and could contribute to the growing use of blood-based biomarkers in brain-health care.